Coherus BioSciences
$20.229876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$20.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$1.08 (-5.07%) As of 3:23 PM EST today
-$1.08 (-5.07%) Today
Why Robinhood?
You can buy or sell CHRS and other stocks, options, ETFs, and crypto commission-free!
About CHRS
Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Read More Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Employees
232
Headquarters
Redwood City, California
Founded
2010
Market Cap
1.58B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.21M
High Today
$21.63
Low Today
$20.10
Open Price
$21.41
Volume
701.72K
52 Week High
$23.91
52 Week Low
$12.95
Collections
Analyst Ratings
100%
of 8 ratings
Buy
100%
Hold
0%
Sell
0%
CHRS Earnings
-$0.92
-$0.37
$0.17
$0.72
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
$0.72 per share
Actual
Available Feb 27, After Hours
People Also Bought
Corbus Pharmaceuticals
49,279
$5.25
+1.45%Viking Therapeutics
39,738
$6.20
-2.75%Amarin
16,600
$16.38
-6.40%Bristol-Myers Squibb
7,788
$61.96
-0.29%Aurora Cannabis
673,670
$1.52
+0.33%TherapeuticsMD
13,705
$1.76
-4.86%Bristol-Myers Squibb Comp...
$3.50
-0.57%AbbVie
27,119
$88.49
-0.77%Catalyst Pharmaceuticals
54,587
$4.65
+2.65%Sangamo Therapeutics
4,950
$6.85
+0.74%Tilray
43,930
$15.98
-3.56%Intra-Cellular Therapies
3,535